View Older Stories View More Recent Stories
-
Biotech Acquisition (BIOT) and Blade Therapeutics Announce Effectiveness of Registration Statement, Signs $75M Committed Equity Financing
-
Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combinat
-
Form 3 PepGen Inc. For: May 05 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Illumina Reports Financial Results for First Quarter of Fiscal Year 2022
-
Illumina (ILMN) Partners with Deerfield Management to Accelerate Drug Development
-
Illumina and Deerfield Management partner to accelerate drug development
-
Lumos Pharma, Inc. (LUMO) Enters Collaboration with Massachusetts General Hospital to Evaluate LUM-201
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
-
Apertura Announces Fit4Function AAV Capsid Engineering Platform and In Vivo Proof-of-Concept Data to Be Presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
-
Pre-Open Stock Movers 04/27: Mattel Up on Takeover Talk, Microsoft and Visa Gain on Earnings; NCR, Boeing, Google Drop Post Earnings (more...)
-
Acutus Medical (AFIB) Announces Debt Refinancing, Left-Heart Access Portfolio Sale
-
Acutus Medical Announces Agreements to Fund Strategic Growth Priorities
-
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
-
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
-
Apertura Gene Therapy Launches with $67M Series A Financing from Deerfield and an Innovative Technology Platform to Develop Genetic Medicines
-
Valneva SE (VALN) Enters Upsized $40M Financing Arrangement with Deerfield and OrbiMed
-
Vaccines company Valneva secures new financing with U.S firms Deerfield and OrbiMed
-
Valneva Announces Upsized Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
-
Valneva Announces Upsized Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
-
Aurion Biotech Raises $120 Million from Deerfield Management, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
-
Dracen Pharmaceuticals announces two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
-
Biotech Acquisition (BIOT) Files Amended S4 for Proposed Merger with Blade Therapeutics
-
Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
-
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
-
Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund
-
AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals
-
Nuvalent (NUVL) Appoints Anna Protopapas as Chair of Board of Directors
-
Nuvalent Appoints Anna Protopapas as Chair of Board of Directors
-
Miravo Healthcare™ Announces 2021 and Fourth Quarter Results
-
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
-
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
-
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
-
Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
-
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
-
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Dracen Pharmaceuticals announces oral presentation at Festival of Biologics World Immunotherapy Congress 2022
-
For The Second Year in a Row, Two Einstein Research Teams Win Competitive XSeed Awards
-
Deerfield Management Announces XSeed Award Winners
-
Break Into the Boardroom Fills Over 50 Healthcare Board Seats With Women Leaders
-
Blade Therapeutics to Participate in Upcoming Investor Conferences
-
Vibliome Therapeutics Spins Off New Company, Raises Additional Funding
-
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
-
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
-
Somatus Raises $325M to Deliver Proven Value-Based Kidney Care Model to More Americans with Kidney Disease
-
Advancium Health Network and Silicon Valley Bank to Launch Not-For-Profit Cure Innovation Labs℠ Accelerating Early Stage Life Science Companies
